Methods
Methods

Statistical analysis
The overall survival was calculated from diagnosis to death or lung transplantation with data censured at June 1st, 2019. The cumulative survival rate was calculated using Kaplan-Meier method and the difference in the survival time between the two groups (stable and progressors) was assessed with log-rank test. Clinical characteristics and radiological scores were evaluated to determine their relationship with disease progression in a univariate analysis of Cox proportional hazards regression testing. Variables with an association statistically significant or almost significant (0.05 < p < 0.09) with overall survival at univariate analysis were included in a multivariate Cox proportional hazard regression test to find the factors independently associated with disease progression.
Results
Survival analysis and association between clinical -radiological parameters and survival
Survival of stable patients was not statistically different from survival of progressors (HR 1.93, 95% CI 0.85 -4.41; p= 0.11) ( Figure S1 To detect factors predictive of disease progression in the entire IPF population, we used Cox proportional hazards regression analysis. Univariate analysis of factors associated with survival revealed that FVC (liters (L)) at diagnosis, FEV1 (L) at diagnosis, DLCO after one year of antifibrotic drug, FVC (L) and FVC % pred. after one year of antifibrotic drug, 6-minute walking test (6MWT) after one year of antifibrotic drug and IS+HC in HRCT1 had significant positive association with disease progression in the entire IPF population (Table S1 ). Of interest, univariate analysis of factors associated with survival showed that 6MWT at diagnosis, 6MWT change over one year of treatment, ΔHC, IS+HC in HRCT2 had an almost significant positive association with disease progression. Multivariate analysis performed using variables having statistical significance or almost significant in univariate analysis, revealed that only 6MWT at diagnosis (HR: 3.64; 95%CI: 1.16 -11.42; p = 0.03) and 6MWT change over one year of treatment (HR: 0.32; 95%CI: 0.11 -0.91; p = 0.03) are independent predictors of disease progression in IPF patients. ≥ 4.5% vs. < 4.5%)  FVC after 1-yr of antifibrotic drug (≥ 75% vs. < 75%)  FVC after 1-yr of antifibrotic drug (≥ 2.6L vs. < 2.6L)  FVC decline after 1-yr of antifibrotic drug (≥ 86ml vs. < 86ml)  6MWT at diagnosis (≥ 400 mt vs. < 400 mt)  6MWT after 1-yr of antifibrotic drug (≥ 400 mt vs. < 400 mt) 6MWT change (Δ) (≥ 20 mt vs. < 20 mt) 
